Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial

OBJECTIVE: Everolimus, an inhibitor of the mammalian target of rapamycin, has recently demonstrated efficacy and safety in a Phase III, double-blind, randomized trial (RADIANT-3) in 410 patients with low- or intermediate-grade advanced pancreatic neuroendocrine tumours. Everolimus 10 mg/day provided...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Tetsuhide, Okusaka, Takuji, Ikeda, Masafumi, Igarashi, Hisato, Morizane, Chigusa, Nakachi, Kohei, Tajima, Takeshi, Kasuga, Akio, Fujita, Yoshie, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448379/
https://www.ncbi.nlm.nih.gov/pubmed/22859827
http://dx.doi.org/10.1093/jjco/hys123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448379/
https://www.ncbi.nlm.nih.gov/pubmed/22859827
http://dx.doi.org/10.1093/jjco/hys123

Ejemplares similares